Evidence map›Paper›PMID 34252250›Full record

ArticleCancer science2021

A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.

Asami Yagi, Yutaka Ueda, Satoshi Nakagawa, Tatsuo Masuda, Takashi Miyatake, Sayaka Ikeda, Hazuki Abe, Kei Hirai, Masayuki Sekine, Etsuko Miyagi and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Asami YagiDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-3222-5963
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-8760-6379
Satoshi NakagawaDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tatsuo MasudaStemRIM Institute of Regeneration-Inducing Medicine, Osaka University, Osaka, Japan.
Takashi MiyatakeDepartment of Obstetrics and Gynecology, Osaka Police Hospital, Osaka, Japan.
Sayaka IkedaCenter for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7948-8990
Hazuki AbeDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kei HiraiGraduate School of Human Sciences, Osaka University, Osaka, Japan.
Masayuki SekineDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Etsuko MiyagiDepartment of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID https://orcid.org/0000-0002-5492-0844
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Tomio NakayamaCenter for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Tadashi KimuraDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
The University of Osaka · JPNiigata University · JPOsaka Police Hospital · JPOsaka University of Human Sciences · JPYokohama City University · JP

Funding

Health and Labour Sciences Research 20EA1025Japanese Agency for Medical Research and Development #17ck0106369s0101
6 · The paper itself

Abstract

In Japan, the age-adjusted incidence of cervical cancer has been increasing constantly and rapidly among younger women. We set out to accurately confirm the effectiveness of the HPV vaccine in Japan. Data were collected for women born in the fiscal year (FY) 1990 to 1997, who became eligible for their 20-y-old cervical cancer screening between the FY 2010 to 2017. The adjusted incidence of cervical intraepithelial neoplasia (CIN)1+ in women born in FY 1990 to 1993, that is those who reached the national vaccination target age prior to the introduction of publicly subsidized HPV vaccinations, referred here after as "the pre-introduction generation", was 1.42% (242/17 040). The incidence in the "vaccination generation" (women born in FY 1994 to 1997, that is those who were heavily vaccinated as a group when they were of the nationally targeted age of 13-16) was 1.66% (135/8020). There was no significant difference between these incidence rates. However, our FY birth year-by-year analysis revealed that the incidence of CIN1+ was obviously lower than that predicted based on just the trend for CIN1+ seen in the pre-introduction generation. Our analysis revealed that the incidence of CIN3+ was obviously lower in the vaccination generation than in the pre-introduction generation (P = .0008). The incidence of CIN was already tending to increase in both the pre-introduction and vaccination generations. The changes in CIN incidence by individual birth FY must be examined to accurately determine the actual effects of the HPV vaccine for reducing mild cervical lesions.

Indexed as

AdolescentFemaleHumansIncidenceJapanPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesTreatment OutcomeUterine Cervical DysplasiaUterine Cervical NeoplasmsVaccinationYoung AdultPapillomavirus Vaccinesbirth yearcancer screeningcervical cancerCINHPV vaccine

Identifiers

PMID34252250
PMCPMC8409296
OpenAlexW3178372143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.